ABM 2752
Alternative Names: ABM-2752Latest Information Update: 30 May 2023
At a glance
- Originator ABM Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Hematopoietic progenitor kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 14 Apr 2023 ABM Therapeutics plans to file an IND application for Solid tumours in 2023
- 14 Apr 2023 Adverse events, pharmacokinetics and pharmacodynamics data from a preclinical study in solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 14 Apr 2023 ABM Therapeutics plans a clinical trial for Solid tumours